PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
https://www.zacks.com/stock/news/2257703/ptc-therapeutics-ptct-expected-to-beat-earnings-estimates-can-the-stock-move-higher?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2257703
Apr 18, 2024 - PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0
Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More
https://www.zacks.com/stock/news/2244198/biotech-stock-roundup-gern-crnx-gain-on-updates-bmy-s-car-t-cell-therapy-news-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2244198
Mar 21, 2024 - Geron Corporation (GERN) and Crinetics Pharmaceuticals (CRNX) gain on positive regulatory and study updates.
0
PTC Therapeutics (PTCT) Up on Positive Regulatory Updates
https://www.zacks.com/stock/news/2243692/ptc-therapeutics-ptct-up-on-positive-regulatory-updates?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2243692
Mar 20, 2024 - PTC Therapeutics (PTCT) submits BLA for gene therapy Upstaza to the FDA and announces plans to resubmit its application for Translarna to the regulatory body. Its shares rise on these updates.
0
PTC Therapeutics, Inc. (PTCT) Q4 2023 Earnings Call Transcript
https://seekingalpha.com/article/4675146-ptc-therapeutics-inc-ptct-q4-2023-earnings-call-transcript?source=feed_sector_transcripts
Feb 29, 2024 - PTC Therapeutics, Inc. (NASDAQ:NASDAQ:PTCT) Q4 2023 Earnings Conference Call February 28, 2024 4:30 PM ETCompany ParticipantsRon Aldridge - Senior Director,...
0
Here's What Key Metrics Tell Us About PTC Therapeutics (PTCT) Q4 Earnings
https://www.zacks.com/stock/news/2234255/here-s-what-key-metrics-tell-us-about-ptc-therapeutics-ptct-q4-earnings?cid=CS-ZC-FT-fundamental_analysis|nfm-2234255
Feb 29, 2024 - While the top- and bottom-line numbers for PTC Therapeutics (PTCT) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
0
PTC Therapeutics (PTCT) Reports Q4 Loss, Lags Revenue Estimates
https://www.zacks.com/stock/news/2234185/ptc-therapeutics-ptct-reports-q4-loss-lags-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2234185
Feb 29, 2024 - PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -182.76% and 2.80%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
0
PTC Therapeutics (PTCT) to Report Q4 Results: Wall Street Expects Earnings Growth
https://www.zacks.com/stock/news/2225553/ptc-therapeutics-ptct-to-report-q4-results-wall-street-expects-earnings-growth?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2225553
Feb 13, 2024 - PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0
Biogen's (BIIB) Rare Disease Drug Skyclarys Gets CHMP Nod in EU
https://www.zacks.com/stock/news/2199443/biogen-s-biib-rare-disease-drug-skyclarys-gets-chmp-nod-in-eu?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2199443
Dec 18, 2023 - Biogen (BIIB) gets positive CHMP opinion recommending marketing authorization to Skyclarys in the EU for the treatment of Friedreich's ataxia in patients aged 16 years and older.
0
Pages: 1
Page 1